Detection of Minimal Residual Disease in Leukaemia by RT-PCR

Methods in Molecular Biology

Volumn 688, Issue , 2011, Pages 269-280

  Mason, Joanne ^a   Griffiths, Mike ^a  

^a BIRMINGHAM CHILDREN S HOSPITAL NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

Fusion gene; Leukaemia; Molecular monitoring; MRD; RT PCR

Indexed keywords

RNA;

AGAR GEL ELECTROPHORESIS; ARTICLE; GENETICS; HUMAN; ISOLATION AND PURIFICATION; LEUKEMIA; METHODOLOGY; MINIMAL RESIDUAL DISEASE; PATHOLOGY; REVERSE TRANSCRIPTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; STATISTICS;

ELECTROPHORESIS, AGAR GEL; HUMANS; LEUKEMIA; NEOPLASM, RESIDUAL; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION; RNA; STATISTICS AS TOPIC;

EID: 79952116722     PISSN: 10643745     EISSN: 19406029     Source Type: Book Series    
DOI: 10.1007/978-1-60761-947-5_18     Document Type: Chapter

References (9)

1. Mullis, KB and Faloona, FA (1987) Specific synthesis of DNA in vitro via a polymerase-catalyzed chain reaction. Methods Enzymol. 155, 335–350.
2. Cross NCP, Lin F, Chase A, Bungey J, Hughes TP, Goldman JM. (1993) Competitive PCR to estimate the number of BCR–ABL transcripts in chronic myeloid leukemia patients after bone marrow transplantation. Blood 82, 1929–1936.
3. Hochhaus A, Lin F, Reiter A, Skladny H, Mason PJ, van Rhee F, Shepherd PC, Allan NC, Hehlmann R, Goldman JM, Cross NC (1996) Quantification of residual disease in chronic myelogenous leukemia patients on interferon-alpha therapy by competitive polymerase chain reaction. Blood 87, 1549–1555.
4. Gabert J, Beillard E, van der Velden VH, Bi W, Grimwade D, Pallisgaard N, Barbany G, Cazzaniga G, Cayuela JM, Cavé H, Pane F, Aerts JL, De Micheli D, Thirion X,Pradel V, González M, Viehmann S, Malec M, Saglio G, van Dongen JJ. (2003) Standardization and quality control studies of ‘real-time’ quantitative reverse transcriptase polymerase chain reaction of fusion gene transcripts for residual disease detection in leukemia – a Europe Against Cancer program. Leukemia 17, 2318–2357.
5. van Dongen JJ, Macintyre EA, Gabert JA, Delabesse E, Rossi V, Saglio G, Gottardi E, Rambaldi A, Dotti G, Griesinger F, Parreira A, Gameiro P, Diáz MG, Malec M,Langerak AW, San Miguel JF, Biondi A. (1999) Standardized RT-PCR analysis of fusion gene transcripts from chromosome aberrations in acute leukemia for detection of minimal residual disease. Report of the BIOMED-1 Concerted Action: investigation of minimal residual disease in acute leukemia. Leukemia 13, 1901–1928.
6. Hughes T, Deininger M, Hochhaus A, Branford S, Radich J, Kaeda J, Baccarani M, Cortes J, Cross NC, Druker BJ, Gabert J, Grimwade D, Hehlmann R, Kamel-Reid S, Lipton JH, Longtine J, Martinelli G, Saglio G, Soverini S, Stock W, Goldman JM. (2006) Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: review and recommendations for harmonizing current methodology for detecting BCR– ABL transcripts and kinase domain mutations and for expressing results. Blood 108, 28–37.
7. Thörn I, Olsson-Strömberg U, Ohlsen C, Jonsson AM, Klangby U, Simonsson B, Barbany G. (2005) The impact of RNA stabilization on minimal residual disease assessment in chronic myeloid leukemia. Haematologica 90, 1471–1476.
8. Kwok, S and Higuchi, R (1989) Avoiding false positives with PCR. Nature 339, 237–238.
9. O’Connell, J (2002) The Basics of RT-PCR, in RT-PCR protocols, O’Connell, J (ed) Humana, Totowa, NJ, pp. 19–25